Loading…
Clinical-stage biotech developing GLP-1/GIP obesity drugs and a thyroid-receptor agonist for fatty liver disease.
Clinical-stage biotech developing GLP-1/GIP obesity drugs and a thyroid-receptor agonist for fatty liver disease.
Has no product on sale and no revenue, so trial costs are paid from cash raised by selling shares. Its main drug candidate comes as a weekly injection and a daily tablet version, and a partnership or licence with a larger drug company would be the way to share the cost of late-stage trials and a launch.
Moat: none (IP / patents). No approved products yet; must prove differentiation versus Novo Nordisk and Eli Lilly incumbents.
Headquarters: San Diego, California, US · Founded: 2012 · Employees: 53
Size Viking Therapeutics (VKTX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.42B, the 1449th largest of 3,117 United States companies the cockpit tracks. Shares closed at $26.84 on 6 Nov 2026.
Performance Over six months the shares fell 16.9%, against +2.2% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd lowest of 20 in its peer set.
Credit Viking Therapeutics has 1 bond outstanding ($259M).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$494,000 | -$431,000 | -$346,000 | -$292,000 | -$291,000 |
| EBITDA | -$648M | -$393M | -$151M | -$101M | -$70.1M |
| Net income | -$627M | -$360M | -$110M | -$85.9M | -$68.9M |
| Free cash flow | -$463M | -$279M | -$87.8M | -$73.4M | -$48.4M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 |
| Total debt | $255M | $137,000 | $1.12M | $1.26M | $1.56M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Viking Therapeutics VKTX | $3.42B | -17% | n/a | n/a | n/a | n/a |
| Novo Nordisk A/S NOVO-B.CO | $190B | -7% | +6% | 48% | 4.0× | 0.1% |
| Lilly (Eli) LLY | $1.27T | +43% | +46% | 51% | 15.2× | 5.9% |
| Amgen AMGN | $249B | +40% | +9% | 36% | 7.4× | 1.8% |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | $1.45B | -48% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VKTX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.2% | +3.5% | 6th lowest of 21 |
| 6-month return | -16.9% | +2.2% | 2nd lowest of 20 |
| Distance from 52-week high | -37.8% | -23.8% | 3rd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Viking Therapeutics VKTX | United States | $3.42B | -17% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.41B | -37% | +33% | 12% | 3.7× | 15.2% | +61.4% |
| Tarsus Pharmaceuticals TARS | United States | $3.38B | +12% | +86% | -10% | 4.6× | 31.9% | +159.5% |
| Piramal Pharma PPLPHARMA.NS | India | $3.37B | +30% | +9% | 3% | 3.8× | n/a | n/a |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.47B | +2% | +3% | 19% | 3.1× | -2.2% | +12.0% |
| Wockhardt WOCKPHARMA.NS | India | $3.35B | +19% | +26% | 13% | 8.9× | 56.9% | +4.2% |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| China National Medicines 600511.SS | China | $3.31B | +2% | +3% | 4% | 0.3× | -9.8% | +5.4% |
| China Medical System 0867.HK | Hong Kong | $3.30B | -16% | +15% | 20% | 2.1× | 2.9% | +2.7% |
| Acutaas Chemicals ACUTAAS.NS | India | $3.28B | +39% | +45% | 36% | 19.3× | n/a | n/a |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.60B | -13% | +136% | 29% | 12.8× | 20.5% | +98.4% |
| Viridian Therapeutics VRDN | United States | $3.23B | +72% | -63% | -1,781% | 99.3× | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.63B | -7% | +27% | 18% | 2.7× | -2.8% | +10.6% |
| Organon & OGN | United States | $3.64B | +4% | -3% | 20% | 1.8× | -4.5% | -1.0% |
| Arcutis Biotherapeutics ARQT | United States | $3.21B | +21% | +76% | 7% | 6.7× | 48.9% | +367.3% |
| ACADIA Pharmaceuticals ACAD | United States | $3.66B | -5% | +12% | 8% | 2.4× | 16.7% | +19.4% |
| Tasly Pharmaceutical 600535.SS | China | $3.20B | -5% | -4% | 19% | 2.3× | -7.6% | -9.6% |
| Chengdu Kanghong Pharmaceutical 002773.SZ | China | $3.18B | -7% | -11% | 24% | 3.6× | -2.2% | +7.0% |
| Livzon Pharmaceutical 1513.HK | Hong Kong | $3.69B | -11% | -10% | 19% | 2.3× | -7.7% | +2.0% |
| Amylyx Pharmaceuticals AMLX | United States | $3.70B | +97% | +100% | n/a | n/a | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.73B | +18% | -16% | 10% | 2.8× | 6.3% | +4.5% |
Viking Therapeutics has 1 bond outstanding with $259M face value.